Opendata, web and dolomites

Everfill

Improving the Quality of Life of Millions through the Revolutionary Approach in Dermal Regeneration Care

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Everfill project word cloud

Explore the words cloud of the Everfill project. It provides you a very rough idea of what is the project "Everfill" about.

incurable    bioengineered    allogeneic    proof    safe    severe    faster    unhealthy    clinical    venture    bioactive    everfill    estimate    first    regenerate    dimensions    classification    conducting    tampere    global    initial    lifestyle    million    wounds    triggers    diseases    patient    superior    regulatory    regeneration    gaining    university    ageing    uses    instrument    sedative    launch    oy    populations    extracted    spin    revolutionize    commercialization    revenue    countries    combination    350    diet    massive    experimental    tissues    capital    deep    normal    savings    ongoing    off    round    contains    ipr    2019    necrosis    trigger    scientific    reg    feasibility    patented    amputations    revenues    healing    everyday    trials    thorough    invested    leg    batch    care    half    tolerated    occurrence    defects    curing    material    dressings    damaged    building    wound    distorts    business    21    commercial    millions    tissue    life    sme    human    sales    health    quality    people    diabetes    body    outcomes    gels    investors   

Project "Everfill" data sheet

The following table provides information about the project.

Coordinator
EVERFILL OY 

Organization address
address: FREDRIKINKATU 25 A 17
city: HELSINKI
postcode: 120
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Project website http://www.everfill.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EVERFILL OY FI (HELSINKI) coordinator 50˙000.00

Map

 Project objective

The combination of ageing populations, sedative lifestyle and unhealthy diet results in increase in such diseases as diabetes. One of the outcomes of diabetes is the occurrence of very severe and deep leg wounds. As diabetes distorts the body’s normal tissue regeneration processes, it often results in necrosis and amputations, which are still everyday practice even in developed countries. Everfill Oy is a university spin-off that has developed Everfill®, a patented allogeneic bioengineered product that will revolutionize the care of wounds. Everfill® uses extracted human bioactive growth factors that trigger the patient’s body to regenerate damaged tissues. This results in faster and more thorough healing. As Everfill® contains only human material and triggers the patient to regenerate own tissue, it is a superior product for dressings and wound gels. It is safe and well tolerated and has no side effects. Everfill® will enable curing currently incurable tissue defects and wounds, achieve massive savings in health care, and improve the quality of life for millions of people. Our estimate of its global revenue potential is over €350 million per year. So far €0.7 million were invested into the scientific research conducted at the University of Tampere and related to Everfill® product. In order to launch the product commercialization phase, we are looking for €5 million funding for 2019-21, of which half from venture capital investors within the ongoing round A and another half from the SME Instrument. This funding will be used for gaining EU and US regulatory classification for the product, building up business process proof of concept to produce the product for clinical trials, and conducting the first phase of clinical trials in EU. Initial sales revenues from experimental patient care using the first batch of product will be generated during the project. Our SME-1 feasibility study will have IPR, legal, commercial and operational feasibility dimensions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EVERFILL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EVERFILL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

HUD (2018)

COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLES

Read More  

C-Air (2018)

An innovative, reliable, lifesaving industrial air purification system that contains, cleans, and purifies air contaminated by toxic gases.

Read More